Posts

Showing posts with the label Meningococcal Vaccines Market

Global Meningococcal Vaccine Market: Trends, Innovations, and Forecasts

The global  meningococcal vaccines market  size is expected to reach USD 5.28 billion by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. For instance, according to ECDC, it was estimated that in 2017, 3,221 confirmed cases were observed in EU member states, wherein 58% cases were found in the U.K., France, Spain, and Germany. Moreover, a high incidence of meningitis disease is found in the “meningitis belt” of sub-Saharan Africa, and approximately 30,000 cases are reported every year in this region.   In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth. For instance, in April 2020, Sanofi received FDA approval for its MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive meningococcal disorders in individuals at least two years old. The increase in ...

Meningococcal Vaccines Market size is expected to reach USD 4.92 billion by 2030

  Meningococcal Vaccines Industry Overview The global meningococcal vaccines market size was valued at USD 2.88 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030.   The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Moreover, increasing immunization programs, growing awareness about the disease, and increasing R&D activities pertaining to meningococcal vaccines are expected to fuel the market growth during the forecast period.   Gather more insights about the market drivers, restrains and growth of the Global Meningococcal Vaccines Market   The overall market experienced a decline in 2020 owing to the COVID-19 pandemic. The net sales of Menactra, Menveo, Nimenrix, Trumenba, and Bexsero were nega...